Search Results - "Forbes, John F"

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial by Cuzick, Jack, Prof, Sestak, Ivana, PhD, Cawthorn, Simon, MD, Hamed, Hisham, MD, Holli, Kaija, Prof, Howell, Anthony, Prof, Forbes, John F, Prof

“…Summary Background Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at…”
Get full text

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial by Cuzick, Jack, Prof, Sestak, Ivana, PhD, Baum, Michael, Prof, Buzdar, Aman, Prof, Howell, Anthony, Prof, Dowsett, Mitch, Prof, Forbes, John F, Prof

“…Summary Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with…”
Get full text

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V by Colleoni, Marco, Sun, Zhuoxin, Price, Karen N, Karlsson, Per, Forbes, John F, Thürlimann, Beat, Gianni, Lorenzo, Castiglione, Monica, Gelber, Richard D, Coates, Alan S, Goldhirsch, Aron

“…Predicting the pattern of recurrence can aid in the development of targeted surveillance and treatment strategies. We identified patient populations that…”
Get full text

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial by Cuzick, Jack, Prof, Sestak, Ivana, PhD, Forbes, John F, Prof, Dowsett, Mitch, Prof, Knox, Jill, MSc, Cawthorn, Simon, MD, Saunders, Christobel, Prof, Roche, Nicola, MD, Mansel, Robert E, Prof, von Minckwitz, Gunter, MD, Bonanni, Bernardo, MD, Palva, Tiina, MD, Howell, Anthony, Prof

“…Summary Background Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We…”
Get full text

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy by Bradbury, Andrew W., BSc, MD, MBA, FRCSEd, Adam, Donald J., MD, FRCSEd, Bell, Jocelyn, PhD, Forbes, John F., PhD, Fowkes, F. Gerry R., PhD, FRCPE, Gillespie, Ian, MD, FRCR, Ruckley, Charles Vaughan, ChM, FRCSEd, CBE, Raab, Gillian M., PhD

“…Background A 2005 interim analysis of the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial showed that in patients with severe lower limb…”
Get full text

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer by CUZICK, Jack, DOWSETT, Mitch, HOWELL, Anthony, BUZDAR, Aman U, FORBES, John F, PINEDA, Silvia, WALE, Christopher, SALTER, Janine, QUINN, Emma, ZABAGLO, Lila, MALLON, Elizabeth, GREEN, Andrew R, ELLIS, Ian O

“…We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant…”
Get full text

Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial by SESTAK, Ivana, DISTLER, Wolfgang, FORBES, John F, DOWSETT, Mitch, HOWELL, Anthony, CUZICK, Jack

“…Third-generation aromatase inhibitors have been widely used in postmenopausal women for the adjuvant treatment of hormone receptor-positive breast cancer. As…”
Get full text

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial by Forbes, John F, Prof, Sestak, Ivana, PhD, Howell, Anthony, Prof, Bonanni, Bernardo, MD, Bundred, Nigel, Prof, Levy, Christelle, MD, von Minckwitz, Gunter, Prof, Eiermann, Wolfgang, MD, Neven, Patrick, Prof, Stierer, Michael, Prof, Holcombe, Chris, MD, Coleman, Robert E, Prof, Jones, Louise, Prof, Ellis, Ian, Prof, Cuzick, Jack, Prof

“…Summary Background Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with…”
Get full text

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data by Cuzick, Jack, Prof, Sestak, Ivana, PhD, Bonanni, Bernardo, MD, Costantino, Joseph P, DrPH, Cummings, Steve, MD, DeCensi, Andrea, Prof, Dowsett, Mitch, Prof, Forbes, John F, Prof, Ford, Leslie, MD, LaCroix, Andrea Z, Prof, Mershon, John, MD, Mitlak, Bruce H, MD, Powles, Trevor, Prof, Veronesi, Umberto, Prof, Vogel, Victor, Prof, Wickerham, D Lawrence, MD

“…Summary Background Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated risk of disease, but the duration of the effect is unknown…”
Get full text

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial by Cuzick, Jack, Prof, Sestak, Ivana, PhD, Pinder, Sarah E, Prof, Ellis, Ian O, Prof, Forsyth, Sharon, BSc, Bundred, Nigel J, Prof, Forbes, John F, Prof, Bishop, Hugh, MD, Fentiman, Ian S, Prof, George, William D, MD

“…Summary Background Initial results of the UK/ANZ DCIS (UK, Australia, and New Zealand ductal carcinoma in situ) trial suggested that radiotherapy reduced new…”
Get full text

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up by Regan, Meredith M, Dr, Neven, Patrick, MD, Giobbie-Hurder, Anita, MS, Goldhirsch, Aron, MD, Ejlertsen, Bent, MD, Mauriac, Louis, MD, Forbes, John F, FRACS, Smith, Ian, MD, Láng, István, MD, Wardley, Andrew, MD, Rabaglio, Manuela, MD, Price, Karen N, BS, Gelber, Richard D, PhD, Coates, Alan S, MD, Thürlimann, Beat, MD

“…Summary Background Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and…”
Get full text

Preventive therapy for breast cancer: a consensus statement by Cuzick, Jack, Prof, DeCensi, Andrea, MD, Arun, Banu, Prof, Brown, Powel H, Prof, Castiglione, Monica, Prof, Dunn, Barbara, MD, Forbes, John F, Prof, Glaus, Agnes, PhD, Howell, Anthony, Prof, von Minckwitz, Gunter, Prof, Vogel, Victor, MD, Zwierzina, Heinz, Prof

“…Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and…”
Get full text

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received by Bradbury, Andrew W., BSc, MD, MBA, FRCSEd, Adam, Donald J., MD, FRCSEd, Bell, Jocelyn, PhD, Forbes, John F., PhD, Fowkes, F. Gerry R., PhD, FRCPE, Gillespie, Ian, MD, FRCR, Ruckley, Charles Vaughan, ChM, FRCSEd, CBE, Raab, Gillian M., PhD

“…Background An intention-to-treat analysis of randomized Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial data showed that initial…”
Get full text

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis by Sestak, Ivana, PhD, Cuzick, Jack, Prof, Sapunar, Francisco, MD, Eastell, Richard, Prof, Forbes, John F, Prof, Bianco, Angelo R, MD, Buzdar, Aman U, MD

“…Summary Background Joint symptoms (eg, arthralgia and arthritis) are a well-known side-effect of aromatase inhibitors. Low oestrogen concentrations and…”
Get full text

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors by GONG TANG, CUZICK, Jack, COSTANTINO, Joseph P, DOWSETT, Mitch, FORBES, John F, CRAGER, Michael, MAMOUNAS, Eleftherios P, SHAK, Steven, WOLMARK, Norman

“…The 21-gene breast cancer assay recurrence score (RS) is widely used for assessing recurrence risk and predicting chemotherapy benefit in patients with…”
Get full text

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 by COATES, Alan S, KESHAVIAH, Aparna, LDNG, Istvdn, DEL MASTRO, Lucia, SMITH, Ian, CHIRGWIN, Jacquie, NOGARET, Jean-Marie, PIENKOWSKI, Tadeusz, WARDLEY, Andrew, JAKOBSEN, Erik H, PRICE, Karen N, THURLIMANN, Beat, MOURIDSEN, Henning, MAURIAC, Louis, FORBES, John F, PARIDAENS, Robert, CASTIGLIONE-GERTSCH, Monica, GELBER, Richard D, COLLEONI, Marco

“…Previous analyses of the Breast International Group (BIG) 1-98 four-arm study compared initial therapy with letrozole or tamoxifen including patients randomly…”
Get full text

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival prediction model to facilitate clinical decision making by Bradbury, Andrew W., BSc, MD, MBA, FRCSEd, Adam, Donald J., MD, FRCSEd, Bell, Jocelyn, PhD, Forbes, John F., PhD, Fowkes, F. Gerry R., PhD, FRCPE, Gillespie, Ian, MD, FRCR, Ruckley, Charles Vaughan, ChM, FRCSEd, CBE, Raab, Gillian M., PhD

“…Background An intention-to-treat analysis of the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial showed that in patients with severe…”
Get full text

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis by Forbes, John F., PhD, Adam, Donald J., MD, FRCSEd, Bell, Jocelyn, PhD, Fowkes, F. Gerry R., PhD, FRCPE, Gillespie, Ian, MD, FRCR, Raab, Gillian M., PhD, Ruckley, Charles Vaughan, ChM, FRCSEd, CBE, Bradbury, Andrew W., BSc, MD, MBA, FRCSEd

“…Background The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial showed that survival in patients with severe lower limb ischemia (rest…”
Get full text

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial by Sestak, Ivana, Dr, Singh, Shalini, PhD, Cuzick, Jack, Prof, Blake, Glen M, Prof, Patel, Rajesh, PhD, Gossiel, Fatma, MSc, Coleman, Rob, Prof, Dowsett, Mitch, Prof, Forbes, John F, Prof, Howell, Anthony, Prof, Eastell, Richard, Prof

“…Summary Background Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are associated with accelerated bone…”
Get full text

Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial by EWERTZ, Marianne, GRAY, Kathryn P, GELBER, Richard D, COLLEONI, Marco, LANG, István, SMITH, Ian E, COATES, Alan S, GOLDHIRSCH, Aron, MOURIDSEN, Henning T, REGAN, Meredith M, EJLERTSEN, Bent, PRICE, Karen N, THÜRLIMANN, Beat, BONNEFOI, Herve, FORBES, John F, PARIDAENS, Robert J, RABAGLIO, Manuela

“…To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer…”
Get full text